Study on Delivering a Diuretic to the Liver Artery and Blocking the Artery to Target Liver Cancer Cells
Sponsor: Memorial Sloan Kettering Cancer Center
ClinicalTrials ID:NCT03107416
This clinical trial is testing the safety of using a diuretic called Bumetanide, delivered directly into the liver artery, followed by blocking the artery to cut off the blood supply to liver cancer cells. The study aims to find out how different doses of Bumetanide affect patients undergoing this procedure as part of their regular treatment.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate the safety of Bumetanide, a medication commonly used to reduce excess water in the body, when it is delivered directly into the liver artery. This is followed by a procedure to block the artery, aiming to starve liver cancer cells by cutting off their blood supply. The study will test different doses of Bumetanide to observe its effects on patients who are already receiving this treatment as part of their standard care.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with liver cancer (HCC) according to specific medical criteria.
- Any virus status is accepted, such as Hepatitis C.
- Any previous liver treatments are allowed.
- Have liver cancer that cannot be removed by surgery.
- At least 18 years old.
- In good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Have cancer that can be measured by scans.
- Eligible for a procedure to block the blood supply to the tumor.
Exclusion Criteria
- Women who are pregnant or breastfeeding.
- Allergic to Bumetanide or sulfonamides.
- Have liver cancer that can be surgically removed.
- At high risk for liver failure after the procedure, such as having severe liver disease or extensive liver involvement by the tumor.
- Cannot undergo the procedure due to issues like severe allergic reactions to contrast dye or poor kidney function.
- In poor overall health with an ECOG score of 2.
- Have a tumor blocking the main vein to the liver.
- Have advanced cancer with distant spread.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) | 07920 | Basking Ridge | New Jersey |
| Memorial Sloan Kettering Monmouth (Consent and follow-up only) | 07748 | Middletown | New Jersey |
| Memorial Sloan Kettering Bergen (Consent and follow-up only) | 07645 | Montvale | New Jersey |
| Memorial Sloan Kettering Westchester (Consent and follow-up only) | 10604 | Harrison | New York |
| Memorial Sloan Kettering Cancer Center | 10065 | New York | New York |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.